Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcome...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-03-01
Edice:	Cancer Medicine
Témata:	common EGFR mutation dacomitinib epidermal growth factor receptor mutation non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitor
On-line přístup:	https://doi.org/10.1002/cam4.71659
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!